Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

Rating for BiogenBIIB jumped into a new percentile Monday, with an increase from 80 to 84.Please watch the video at Investors ...

(BIIB) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you ...

Here are the top catalysts for the Nasdaq 100 Index and its ETFs, like QQQ and JEPQ, including the upcoming BoJ rate decision ...

Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...

If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.

In this video, Brian T. Hill, MD, PhD, discusses data from the Smart Stop trial assessing the effects of a novel targeted combination therapy in patients with newly diagnosed diffuse large B-cell ...

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.